Drug Trial Radar · NCT07948083
KDTV001 Injection in Patients With Human Papillomavirus (HPV) Types 16, and/or 18, and/or 52 Associated Cervical High-Grade Squamous Intraepithelial Lesion .
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
304
Planned (sponsor's estimate)
Start
Jan 6, 2026
Primary completion
Nov 30, 2027
Study completion Jan 30, 2029
Sponsor
- Lead sponsor
- Wuhan KadGeno Biotechnology Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Nov 19, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
KDTV001 Injection is a non-replicating adenovirus serotype 5 (Ad5)-based therapeutic HPV vaccine developed by Wuhan KadGeno Biotechnology Co., Ltd. It utilizes an engineered adenoviral vector expressing the HPV16/18/52 E6/E7 fusion protein under CMV promoter control, designed to inducing a robust cellular immune response that eradicates HPV-related lesions. This is a Phase I, multicenter, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, immunogenicity, and preliminary efficacy of KDTV001 Injection in participants with HPV types 16, and/or 18, and/or 52-associated cervical HSIL. The study consists of three parts: dose escalation, an immunogenicity expansion cohort (Phase 1), and a dose expansion phase (Phase 2). In Phase 1a, 3+3 dose escalation of KDTV001 Injection will be conducted separately for IM and IC administration, with two ascending dose levels evaluated for each route. During the dose-escalation phase, if a dose cohort is assessed as safe by SRC, an immunogenicity expansion of 10-20 participants may be conducted. Based on Phase 1 safety and immunogenicity data, 1-2 dose levels will be selected for Phase 2 dose expansion for both IC and IM. In the Phase 2 dose-expansion phase, each dose cohort will enroll 30-50 participants. Both phases will consist of a screening period, a treatment and safety follow-up period, an end of study visit (EOS) and a long-term follow-up period.
Conditions
- HPV (Human Papillomavirus)-Associated
- HPV 16/18
- HPV 52
- Cervical High Grade Squamous Intraepithelial Lesion
Interventions
KDTV001Drug
KDTV001 Injection is a non-replicating adenovirus serotype 5 (Ad5)-based therapeutic HPV vaccine developed by Wuhan KadGeno Biotechnology Co., Ltd. It utilizes an engineered adenoviral vector expressing the HPV16/18/52 E6/E7 fusion protein under CMV promoter control, designed to inducing a robust cellular immune response that eradicates HPV-related lesions.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Incidence of Any Adverse Events (AEs), Treatment related AEs (TRAEs) and Serious Adverse Events (SAEs) Following Investigational Treatment for the Duration of the StudyTime frame: From enrollment to 2 years after the first dose.
- Phase 2: Percentage of Participants With No Evidence of Cervical HSIL on Histology and No Evidence of HPV-16 and HPV-18 and HPV-52 in Cervical SamplesTime frame: From enrollment to 36 weeks after the first dose.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
TongJi Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China · Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.